The immunostimulatory activity exerted by the combination of guadecitabine/ICBs assumes even more relevance considering that it induced a significant decrease of CD4+CD25+FoxP3+ Treg cells in the tumor infiltrate, indicating that the net effect of this combination treatment is to shift the balance between effector and regulatory T cell functions toward the former one (Fig. 4A). The gene discussed is CD4; the disease is neoplasm.